A2ML1 Inhibits Esophageal Squamous Cell Carcinoma Progression and Serves as a Novel Prognostic Biomarker

Studies have established a correlation between α2-macroglobulin-like 1 (A2ML1) and the prognosis of lung, pancreatic, and breast cancers; however, research on its involvement in the pathogenesis of esophageal carcinoma remains limited. Therefore, in this study, we aimed to investigate the role of A2...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoyun Zhang, Chaogui Tang, Jianchun Lian, Yuzhang Jiang
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Canadian Journal of Gastroenterology and Hepatology
Online Access:http://dx.doi.org/10.1155/2023/5557546
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850168167033208832
author Xiaoyun Zhang
Chaogui Tang
Jianchun Lian
Yuzhang Jiang
author_facet Xiaoyun Zhang
Chaogui Tang
Jianchun Lian
Yuzhang Jiang
author_sort Xiaoyun Zhang
collection DOAJ
description Studies have established a correlation between α2-macroglobulin-like 1 (A2ML1) and the prognosis of lung, pancreatic, and breast cancers; however, research on its involvement in the pathogenesis of esophageal carcinoma remains limited. Therefore, in this study, we aimed to investigate the role of A2ML1 in the progression of esophageal squamous cell carcinoma (ESCC). Immunohistochemical staining was employed to assess the expression level of A2ML1 protein in both tumor and adjacent normal tissues of patients with ESCC. The Kaplan–Meier method, along with univariate and multivariate Cox risk ratio analyses, was used to determine survival rates and prognostic factors. Furthermore, two human ESCC cell lines, KYSE30 and KYSE150, were used to assess the effect of A2ML1 overexpression on cell proliferation and apoptosis. A human apoptosis antibody kit was also used to analyze the downstream action proteins of A2ML1, and a nude mouse xenotransplantation model was used to evaluate the effect of A2ML1 on ESCC tumorigenesis in vivo. The protein level of A2ML1 in ESCC tissues was significantly lower than that in normal esophageal tissues, and higher A2ML1 protein levels were associated with smaller ESCC tumor sizes and improved tumor-specific survival rates. Multivariate analysis established A2ML1 as a novel independent prognostic factor for ESCC. Moreover, A2ML1 overexpression significantly inhibited ESCC cell proliferation and promoted apoptosis. A2ML1 consistently inhibited tumor growth in mouse models. Furthermore, the human apoptotic antibody kit results showed increased expression of the proliferation-inhibiting protein p21 downstream of KYSE150 cells overexpressing A2ML1. Our findings demonstrate that a correlation exists between A2ML1 and ESCC prognosis and that A2ML1 plays an antitumor role in ESCC progression. This study underscores the potential of A2ML1 as a novel biomarker for predicting the prognosis of ESCC.
format Article
id doaj-art-e61d04b0188f4f128122308db0d126f3
institution OA Journals
issn 2291-2797
language English
publishDate 2023-01-01
publisher Wiley
record_format Article
series Canadian Journal of Gastroenterology and Hepatology
spelling doaj-art-e61d04b0188f4f128122308db0d126f32025-08-20T02:21:02ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27972023-01-01202310.1155/2023/5557546A2ML1 Inhibits Esophageal Squamous Cell Carcinoma Progression and Serves as a Novel Prognostic BiomarkerXiaoyun Zhang0Chaogui Tang1Jianchun Lian2Yuzhang Jiang3Department of Medical LaboratoryDepartment of Medical LaboratoryDepartment of Medical LaboratoryDepartment of Medical LaboratoryStudies have established a correlation between α2-macroglobulin-like 1 (A2ML1) and the prognosis of lung, pancreatic, and breast cancers; however, research on its involvement in the pathogenesis of esophageal carcinoma remains limited. Therefore, in this study, we aimed to investigate the role of A2ML1 in the progression of esophageal squamous cell carcinoma (ESCC). Immunohistochemical staining was employed to assess the expression level of A2ML1 protein in both tumor and adjacent normal tissues of patients with ESCC. The Kaplan–Meier method, along with univariate and multivariate Cox risk ratio analyses, was used to determine survival rates and prognostic factors. Furthermore, two human ESCC cell lines, KYSE30 and KYSE150, were used to assess the effect of A2ML1 overexpression on cell proliferation and apoptosis. A human apoptosis antibody kit was also used to analyze the downstream action proteins of A2ML1, and a nude mouse xenotransplantation model was used to evaluate the effect of A2ML1 on ESCC tumorigenesis in vivo. The protein level of A2ML1 in ESCC tissues was significantly lower than that in normal esophageal tissues, and higher A2ML1 protein levels were associated with smaller ESCC tumor sizes and improved tumor-specific survival rates. Multivariate analysis established A2ML1 as a novel independent prognostic factor for ESCC. Moreover, A2ML1 overexpression significantly inhibited ESCC cell proliferation and promoted apoptosis. A2ML1 consistently inhibited tumor growth in mouse models. Furthermore, the human apoptotic antibody kit results showed increased expression of the proliferation-inhibiting protein p21 downstream of KYSE150 cells overexpressing A2ML1. Our findings demonstrate that a correlation exists between A2ML1 and ESCC prognosis and that A2ML1 plays an antitumor role in ESCC progression. This study underscores the potential of A2ML1 as a novel biomarker for predicting the prognosis of ESCC.http://dx.doi.org/10.1155/2023/5557546
spellingShingle Xiaoyun Zhang
Chaogui Tang
Jianchun Lian
Yuzhang Jiang
A2ML1 Inhibits Esophageal Squamous Cell Carcinoma Progression and Serves as a Novel Prognostic Biomarker
Canadian Journal of Gastroenterology and Hepatology
title A2ML1 Inhibits Esophageal Squamous Cell Carcinoma Progression and Serves as a Novel Prognostic Biomarker
title_full A2ML1 Inhibits Esophageal Squamous Cell Carcinoma Progression and Serves as a Novel Prognostic Biomarker
title_fullStr A2ML1 Inhibits Esophageal Squamous Cell Carcinoma Progression and Serves as a Novel Prognostic Biomarker
title_full_unstemmed A2ML1 Inhibits Esophageal Squamous Cell Carcinoma Progression and Serves as a Novel Prognostic Biomarker
title_short A2ML1 Inhibits Esophageal Squamous Cell Carcinoma Progression and Serves as a Novel Prognostic Biomarker
title_sort a2ml1 inhibits esophageal squamous cell carcinoma progression and serves as a novel prognostic biomarker
url http://dx.doi.org/10.1155/2023/5557546
work_keys_str_mv AT xiaoyunzhang a2ml1inhibitsesophagealsquamouscellcarcinomaprogressionandservesasanovelprognosticbiomarker
AT chaoguitang a2ml1inhibitsesophagealsquamouscellcarcinomaprogressionandservesasanovelprognosticbiomarker
AT jianchunlian a2ml1inhibitsesophagealsquamouscellcarcinomaprogressionandservesasanovelprognosticbiomarker
AT yuzhangjiang a2ml1inhibitsesophagealsquamouscellcarcinomaprogressionandservesasanovelprognosticbiomarker